C4 Therapeutics Makes Auspicious Debut With Roche Tie-Up, $73m Series A

On the strength of research licensed from Dana-Farber Cancer Institute, C4 will develop targeted protein degradation therapeutics against disease-causing proteins in a range of therapeutic areas that could include cancer and the central nervous system.